Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines

Journal of Oral Pathology and Medicine

Volumn 40, Issue 10, 2011, Pages 739-746

  Farnebo, Lovisa ^a   Jerhammar, Fredrik ^b   Ceder, Rebecca ^c   Grafström, Roland C ^c,e   Vainikka, Linda ^a   Thunell, Lena ^b   Grénman, Reidar ^d   Johansson, Ann Charlotte ^b   Roberg, Karin ^a,b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF TURKU   (Finland)

^e VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Bcl 2 family; Head and neck tumors; P53 Arg72Pro; Radiotherapy; Survivin

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 70; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; SURVIVIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; DNA REPAIR; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MALE; MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOSENSITIVITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARGININE; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENOME, HUMAN; HEAD AND NECK NEOPLASMS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROLINE; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054092775     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01036.x     Document Type: Article

References (40)

1. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008; 371: 1695-709.
2. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-52.
3. Lo Muzio L, Pannone G, Staibano S, et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003; 89: 2244-8.
4. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
5. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-9.
6. Tanaka C, Uzawa K, Shibahara T, et al. Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res 2003; 82: 607-11.
7. Reed JC. Bcl-2 family proteins. Oncogene 1998; 17: 3225-36.
8. Guo B, Cao S, Toth K, et al. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 2000; 6: 718-24.
9. Hitt R, Ciruelos E, Amador ML, et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005; 41: 453-60.
10. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.
11. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-73.
12. Jones AS, Roland NJ, Field JK, et al. The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. Clin Otolaryngol Allied Sci 1994; 19: 63-9.
13. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005; 86: 347-63.
14. Garrido C, Brunet M, Didelot C, et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5: 2592-601.
15. da Costa Andrade VC, Parise O Jr, Hors CP, et al. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82: 53-7.
16. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513-30.
17. Vens C, Hofland I, Begg AC. Involvement of DNA polymerase beta in repair of ionizing radiation damage as measured by in vitro plasmid assays. Radiat Res 2007; 168: 281-91.
18. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27: 247-54.
19. Alsbeih G, El-Sebaie M, Al-Harbi N, et al. Radiosensitivity of human fibroblasts is associated with amino acid substitution variants in susceptible genes and correlates with the number of risk alleles. Int J Radiat Oncol Biol Phys 2007; 68: 229-35.
20. Jayasurya R, Francis G, Kannan S, et al. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer 2004; 109: 710-6.
21. Couture C, Raybaud-Diogene H, Tetu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002; 94: 713-22.
22. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007; 12: 303-12.
23. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005; 42: 694-8.
24. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
25. Farnebo L, Jerhammar F, Vainikka L, et al. Number of negative points: a novel method for predicting radiosensitivity in head and neck tumor cell lines. Oncol Rep 2008; 20: 453-61.
26. Farnebo L, Jedlinski A, Ansell A, et al. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med 2009; 24: 549-56.
27. Nilsson JA, Hedberg JJ, Vondracek M, et al. Alcohol dehydrogenase 3 transcription associates with proliferation of human oral keratinocytes. Cell Mol Life Sci 2004; 61: 610-7.
28. Pekkola-Heino K, Jaakkola M, Kulmala J, et al. Comparison of cellular radiosensitivity between different localizations of head and neck squamous-cell carcinoma. J Cancer Res Clin Oncol 1995; 121: 452-6.
29. Grenman R, Burk D, Virolainen E, et al. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 1989; 44: 131-6.
30. Fertil B, Deschavanne PJ, Gueulette J, et al. In vitro radiosensitivity of six human cell lines II. Relation to the RBE of 50-MeV neutrons. Radiat Res 1982; 90: 526-37.
31. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
32. Zhuang SM, Cochran C, Goodrow T, et al. Genetic alterations of p53 and ras genes in 1, 3-butadiene- and 2', 3'-dideoxycytidine-induced lymphomas. Cancer Res 1997; 57: 2710-4.
33. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008; 452: 571-9.
34. Silva P, Homer JJ, Slevin NJ, et al. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. Clin Otolaryngol 2007; 32: 337-45.
35. Nix P, Cawkwell L, Patmore H, et al. Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 2005; 92: 2185-9.
36. Xu L, Yang D, Wang S, et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005; 4: 197-205.
37. Blons H, Laurent-Puig P. TP53 and head and neck neoplasms. Hum Mutat 2003; 21: 252-7.
38. Nguyen NP, Chi A, Nguyen LM, et al. Human papillomavirus-associated oropharyngeal cancer: a new clinical entity. QJM 2010; 103: 229-36.
39. Erjala K, Pulkkinen J, Kulmala J, et al. Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro. Anticancer Res 2002; 22: 3135-42.
40. Kaufman S and Loré JM Jr. TNM classification and disease description in head and neck cancer. Am J Surg 1978; 136: 469-73.